Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 11:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hyperinsulinemia Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Stress and Sugar Synergy

NCT02143011
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Resistance, Dyslipidemia
Interventions
orange juice, sucrose
Other
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 40 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 25, 2026, 11:40 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome

NCT00759291
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
acipimox, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 25, 2026, 11:40 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Dietary Lipid Induced Insulin Resistance

NCT02757560
View directory record Official record
Conditions
Insulin Resistance
Interventions
SFA diet, MUFA diet, CARB diet
Other
Lead sponsor
Phoenix VA Health Care System
Federal
Eligibility
40 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Sep 25, 2026, 11:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Sitting and Moderate Exercise on Plasma Triglyceride Elevation After a Meal

NCT03098446
View directory record Official record
Conditions
Atherosclerosis, Metabolic Syndrome
Interventions
Prolonged sitting with exercise, Prolonged sitting without exercise
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Sep 25, 2026, 11:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis

NCT00422396
View directory record Official record
Conditions
Hypertriglyceridemia With the Metabolic Syndrome
Interventions
Fenofibrate (drug)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 25, 2026, 11:40 PM EDT
Completed Not applicable Interventional Results available

Effects of Pitavastatin on Insulin Sensitivity and Liver Fat

NCT02290106
View directory record Official record
Conditions
Obesity, Fatty Liver, Nonalcoholic
Interventions
pitavastatin, PLACEBO
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 65 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 25, 2026, 11:40 PM EDT
Recruiting Phase 2 Interventional

Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance

NCT05470504
View directory record Official record
Conditions
Insulin Receptor Mutation, Partial Lipodystrophy
Interventions
Pegvisomant
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 25, 2026, 11:40 PM EDT
Completed Phase 4 Interventional Results available

Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes

NCT01326533
View directory record Official record
Conditions
Pre-diabetes
Interventions
hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Sep 25, 2026, 11:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Leptin Receptors in NASH

NCT00583999
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Metabolic Syndrome
Interventions
no interventions, only regular blood-draw
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 25, 2026, 11:40 PM EDT
Not listed Not applicable Interventional

Go Girls! Fitness Support Group Intervention Effectiveness Study

NCT02117063
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Abnormal Weight Gain, Excess Weight, Insulin Resistance, Premature Adrenarche, Type 2 Diabetes Mellitus
Interventions
Go Girls! Fitness Support Group
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 18 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Sep 25, 2026, 11:40 PM EDT
Completed Phase 3 Interventional

Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

NCT03941236
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
dasiglucagon
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
5 Weeks to 13 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 25, 2026, 11:40 PM EDT
Completed Phase 3 Interventional Results available

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

NCT03371082
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Gan & Lee Insulin Glargine Injection, Lantus®
Biological
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 75 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Birmingham, Alabama • Fresno, California • Newport Beach, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 25, 2026, 11:40 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

NCT06881992
View directory record Official record
Conditions
Tumor Hyperinsulinism (Tumor HI)
Interventions
Ersodetug
Drug
Lead sponsor
Rezolute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Chicago, Illinois • Bethesda, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 25, 2026, 11:40 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Effect of Sitting and Moderate Exercise on Plasma Insulin and Glucose Responses to an Oral Glucose Tolerance Test

NCT04195165
View directory record Official record
Conditions
Sedentary Behavior, Insulin Sensitivity, Sedentary Lifestyle
Interventions
SIT, ACTIVE, EX
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Sep 25, 2026, 11:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Metabolic Effects of Short-term Walnut Consumption in Subjects With the Metabolic Syndrome

NCT00525629
View directory record Official record
Conditions
Metabolic Syndrome, Type 2 Diabetes, Cardiovascular Disease
Interventions
Walnuts, Control
Dietary Supplement
Lead sponsor
Christos Mantzoros
Other
Eligibility
40 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Sep 25, 2026, 11:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Androgen Administration on Inflammation in Normal Women

NCT01753037
View directory record Official record
Conditions
Hyperandrogenism
Interventions
Dehydroepiandrosterone (DHEA), Placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2013 · Synced Sep 25, 2026, 11:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline

NCT00099567
View directory record Official record
Conditions
Cognitive Decline
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
70 Years to 79 Years
Enrollment
2,632 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2005 · Synced Sep 25, 2026, 11:40 PM EDT
Completed Not applicable Interventional

ALL-Active: A Family-Based Lifestyle Program for Pediatric Acute Leukemia Patients

NCT01901367
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia in Remission
Interventions
nutritional intervention, exercise intervention, follow-up care, counseling intervention, quality-of-life assessment, laboratory biomarker analysis, questionnaire administration
Dietary Supplement · Behavioral · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
2 Years to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 25, 2026, 11:40 PM EDT
Completed Phase 2 Interventional

Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women

NCT00666172
View directory record Official record
Conditions
Atherosclerosis, Diabetes Mellitus, Obesity, Dyslipidemia, Hypertension
Interventions
Exercise, Weight Loss
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 25, 2026, 11:40 PM EDT
Not listed Not applicable Interventional

Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency

NCT01804413
View directory record Official record
Conditions
Adults Growth Hormone Deficiency.
Interventions
Pegvisomant, Regular insulin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Sep 25, 2026, 11:40 PM EDT
Completed No phase listed Observational Results available

Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity

NCT04114903
View directory record Official record
Conditions
Type 2 Diabetes, Obesity, Cannabis Use, Insulin Sensitivity
Interventions
Study A: Single use of cannabis flower product, Study B: Ad libitum cannabis use for four weeks or no cannabis use
Other
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
21 Years to 40 Years
Enrollment
233 participants
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 25, 2026, 11:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Healthy Transitions: Menopause Effect on Obesity, Energy Balance, and Insulin

NCT00412269
View directory record Official record
Conditions
Menopause
Interventions
Not listed
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
47 Years to 52 Years · Female only
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2007
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 24, 2016 · Synced Sep 25, 2026, 11:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

NCT04172441
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
dasiglucagon, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
7 Days to 364 Days
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 25, 2026, 11:40 PM EDT
Completed Not applicable Interventional

Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects

NCT00815854
View directory record Official record
Conditions
Schizophrenia
Interventions
Folic Acid, Placebo
Dietary Supplement · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 90 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Sep 25, 2026, 11:40 PM EDT